Synthesis, Antimicrobial Evaluation and Molecular Docking of Some Potential 2,6-disubstituted 1H-Benzimidazoles; Non-Classical Antifolates

Author(s): Sunil Harer*, Manish Bhatia, Vikram Kawade.

Journal Name: Medicinal Chemistry

Volume 15 , Issue 7 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Background: Dihydrofolate reductase is one of the important enzymes for thymidylate and purine synthesis in micro-organisms. A large number of drugs have been designed to inhibit microbial DHFR but over the period of time, some drugs have developed resistance and cross reactivity towards the enzyme. Over the past few decades, benzimidazoles, triazoles and their derivatives have been grabbing the attention of the synthetic chemists for their wide gamut of antibacterial and antifungal activities targeting microbial protein DHFR.

Objective: Our goal behind present investigation is to explore benzimidazoles class of drugs as microbial DHFR inhibitors by studying ligand-receptor binding interactions, in vitro enzyme inhibition assay and confirmation of anti-microbial activity against selected pathogenic microorganisms.

Methods: A library containing thirty novel 2,6-disubstituted 1H-benzimidazoles was synthesized by one pot condensation of o-nitro aniline or 2,4-dinitro aniline with series of aldehydes or acetophenones using Na2S2O4 or SnCl2 respectively and reflux for 5-6hr. Structures of compounds have been confirmed by spectroscopic methods as 1H and 13C NMR, FT-IR and MS. In vitro DHFR inhibition study was performed by using Epoch microplate reader and IC50 of the test compounds was compared with Trimethoprim. In vitro antimicrobial activity was performed against selected clinical pathogens by agar disk diffusion method and MIC (µg/mL) was reported.

Results: Moderate to good level of DHFR inhibition was observed with IC50 values in the range of 7-23 µM. Compounds B1, B19, B22, B24 and B30 expressed 1.1 to 1.4 folds more prominent DHFR inhibitory activity as compared to standard Trimethoprim. Remarkable antimicrobial activity was exhibited by B1, B19, B22, B24 and B30. Molecular docking study revealed perfect binding of test ligands with key amino acids of DHFR as Phe31, Ile94, Ile5, Asp27, Gln32 and Phe36.

Conclusion: Nature of 1H-benzimidazole substituents at position 2 and 6 had influence over magnitude and type of molecular binding and variation in the biological activity. The present series of 1H-benzimidazoles could be considered promising broad-spectrum antimicrobial candidates that deserve in future for preclinical antimicrobial evaluation and development of newer antimicrobial agents targeting microbial DHFR.

Keywords: 1H-benzimidazoles, DHFR, molecular modeling, antimicrobial activity, agar disk diffusion, MIC, IC50.

Singh, N.; Pandurangan, A.; Rana, K.; Anand, P.; Ahmed, A.; Tiwari, A.K. Benzimidazole: A short review of their antimicrobial activity. Int. Curr. Pharm. J., 2012, 1(5), 119-127.
Nadeem, S.; Waquar, A.; Shamsher, A.; Ruhi, A.; Jain, S.; Azad, B.; Akhtar, J. Triazoles as potential bioactive agents. Int. J. Pharm. Sci. Rev. Res., 2011, 8(1), 161-169.
Monika, G.; Shivi, B.J. 1,3,4-Oxadiazole as antimicrobial agents: An overview. Chem. Pharm. Res., 2011, 3(3), 137-147.
Periti, P. Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: A mini review. J. Chemother., 1995, 7(3), 221-223.
Somisetti, N.R.; Ravisankar, T.; Latha, J.; Sudhakar, B.K. Synthesis, characterization and antimicrobial activity of novel biphenyl tetrazoles. Der. Pharma Chem., 2012, 4(3), 1093-1103.
Moni, S.; Prem, M.S.C. Dihydrofolate reductase as therapeutic target for infectious diseases: Opportunities and challenges. Future Med. Chem., 2012, 4(10), 1335-1365.
Bayomi, S.M.; Maarouf, A.R.; Abdel, A.N.I.; Ahmed, A.B.M. Synthesis, molecular modeling study, preliminary antitumor and antimicrobial evaluation of new benzimidazole derivatives. J. Am. Sci., 2013, 9(10), 42-48.
Chowdhury, S.F.; Guerrero, R.H.; Reto, B.R. Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential inhibitors of leishmanial and trypanosomal dihydrofolate reductase. J. Enzyme Inhib. Med. Chem., 2002, 17(5), 293-302.
Hassan, H.S.; El-Messery, S.M.; Al-Omary, F.A.; Al-Rashood, S.T.; Shabayek, M.I.; Abulfadl, Y.S. Habib, El-S.E.; El-Hallouty, S.M.; Fayad, W.; Mohamed, K.M.; El-Menshawi, B.S.; El-Subbagh, H.I. Non-classical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study. Eur. J. Med. Chem., 2013, 66, 135-145.
Cunha, E.F.; Ramalho, T.C.; Maia, R.E.; Fundao, I.D.; Janeiro, R.D.; Teodorico, C.R.; Ricardo, B.D. The search for new DHFR inhibitors: A review of patents, January 2001-February 2005. Expert Opin. Ther. Pat., 2005, 15(8), 967-986.
Yaseen, G.; Jadhav, S. Design, synthesis and antimicrobial activity of 2-mercaptobenzimidazole derivatives. Int. J. Pharma Bio Sci., 2010, 1(4), 281-286.
Lam, T.; Hilgers, M.T.; Cunningham, M.L.; Bryan, P.K.; Kirk, J.N.; Vickie, B.D.; Voon, O.; Michael, T.; Grayson, H.; Karen, J.Y.S.; John, F. Structure based design of new dihydrofolate reductase antibacterial agents: 7-(Benzimidazol-1yl)-2,4-diamino-quinazolines. J. Med. Chem., 2014, 57(3), 651-668.
Ohmeng, K.A.; Barbara, R. Receptor based design of novel dihydrofolate reductase inhibitors; benzimidazole and indole derivatives. J. Med. Chem., 1991, 34(4), 1383-1394.
Jing, X.; Zhu, Q.; Xu, F.; Ren, X.; Li, D.; Yan, C. Rapid one-pot preparation of 2-substituted benzimidazoles from esters using microwave conditions. Synth. Commun., 2006, 36, 2597-2602.
Tandon, V.K.; Kumar, M. BF3Et2 promoted one-pot expeditious and convenient synthesis of 2-substituted benzimidazoles and 3,1,5-benzoxadiazepines. Tetrahedron Lett., 2004, 45, 4185-4191.
Balalaie, S.; Hashemi, M.M.; Akhbari, M. A novel one-pot synthesis of tetrasubstituted imidazoles under solvent free conditions and microwave irradiation. Tetrahedron Lett., 2003, 44(8), 1709-1711.
Rastogi, R.; Sharma, S. 2-amino benzimidazoles in organic synthesis. Synthesis, 1983, 861-866.
Van Vliet, D.S.; Gillespie, P.; Scicinski, J. Rapid one-pot preparation of 2-substituted benzimidazoles from 2-nitroanilines using microwave conditions. Tetrahedron Lett., 2005, 46, 6741-6746.
Hegedus, A.; Hell, Z.; Potor, A. Zeolite-catalyzed environmentally friendly synthesis of benzimidazole derivatives. Synth. Commun., 2006, 36, 3625-3635.
Lin, A.Y.; Isome, Y.; Stewart, E.; Liu, J.F.; Yohannes, D.; Yu, L. Microwave-assisted one step high-throughput synthesis of benzimidazoles. Tetrahedron Lett., 2006, 47, 2883-2892.
Bastien, D.; Ebert, M.C.C.J.C.; Forge, D.; Toulouse, J.; Kadnikova, N.; Perron, F.; Mayence, A.; Huang, T.L.; Eynde, J.V.; Pelletier, J.N. Fragment-based design of symmetrical bis-benzimidazoles as selective inhibitors of the trimethoprim-resistant, type II R67 dihydrofolate reductase. J. Med. Chem., 2012, 55(7), 3182-3192.
Savel, J.; Durand, R. Dihydrofolate reductase inhibitors: New developments in antiparasitic chemotherapy. Expert Opin. Ther. Pat., 2001, 11(8), 1285-1290.
Yuthavonga, Y.; Tarnchompooa, B.; Vilaivanb, T. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc. Natl. Acad. Sci., 2012, 109(42), 16823-16828.
Kisliuk, R.L. The biochemistry of folates. In: Sirotnak, F.M.; Ensminger, W.D.; Burchall, J.J.; Montgomery, J.A. (Eds). Folate antagonists as therapeutic agents; New York: Academic Press. Sirotnak, F.M. John Wiley and Sons, New York, 1984, Vol. 1, pp. 1- 55.
Adane, L.; Bhagat, S.; Arfeen, M. Design and synthesis of guanylthiourea derivatives as potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme. Bioorg. Med. Chem. Lett., 2014, 24, 613-617.
Al-Rashood, S.T.; Hassan, S.G.; El-Messery, S.M.; Nagi, M.N.; Habib, E.E.; Al-Omary, F.A.M.; El-Subbagh, H.I. Synthesis, biological evaluation and molecular modeling study of 2-(1,3,4-thiadiazolyl-thio and 4-methyl-thiazolyl-thio)-quinazolin-4-ones as a new class of DHFR inhibitors. Bioorg. Med. Chem. Lett., 2014, 24, 4557-4567.
Blaney, J.M.; Hansch, C.; Silipo, C.; Vittoria, A. Structure activity relationship of dihydrofolate reductase inhibitors. Chem. Rev., 1984, 84, 333-407.
Schrodinger, L.L.C. (Maestro, version 10.2). New York, 2015.
El-Hamamsy, M.H.; Smith, A.W.; Thompson, A.S.; Threadgill, M.D. Structure based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis. Bioorg. Med. Chem., 2007, 15, 4552-4576.
Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28, 235-242.
Goncalves, A.D.; França, T.C.C.; Caetano, M.S.; Ramalho, T.C. Reactivation steps by 2-PAM of tabun-inhibited human acetylcholinesterase: Reducing the computational cost in hybrid QM/MM methods. J. Biomol. Struct. Dyn., 2014, 32(2), 301-307.
Jimonet, P.; Audiau, F.; Barreau, M.; Blanchard, J.C.; Boireau, A.; Bour, Y.; Coleno, M.A.; Doble, A.; Doerflinger, G.; Huu, C.D.; Donat, M.H.; Duchesne, J.M.; Ganil, P.; Gueremy, C.; Honore, E.; Just, B.; Kerphirique, R.; Gontier, S.; Hubert, P.; Laduron, P.M.; Blevec, J.L.; Meunier, M.; Miquet, J.M.; Nemecek, C.; Pasquet, M.; Piot, O.; Pratt, J.; Rataud, J.; Reibaud, M.; Stutzmann, J.M.; Mignani, S. Riluzole series: Synthesis and in vivo “Antiglutamate” activity of 6-substituted-2-benzothiazolamines and 3-substituted-2-imino-benzothiazolines. J. Med. Chem., 1999, 42(15), 2828-2843.
Tumelty, D.; Schwarz, M.K.; Needels, M.C. Solid phase synthesis of substituted benzimidazoles. Tetrahedron Lett., 1998, 39, 7467-7470.
Schuerman, R.A.; Tumelty, D. The reduction of aromatic nitro groups on solid supports using sodiumhydrosulfite (Na2S2O4). Tetrahedron Lett., 2000, 41, 6531-6535.
Bates, D.; Xia, M.J. A sulfoxide-based ring annelation approach to fused, many-membered ring N,S-heterocycles. Org. Chem., 1998, 63, 9190-9196.
Levai, A. Process for preparing 1,4-benzothiazepine derivatives. Pharmazie, 1980, 35, 680-681.
Bellamy, F.D.; Ou, K. Selective reduction of aromatic nitro compounds with stannous chloride in non acidic and non aqueous medium. Tetrahedron Lett., 1984, 25, 839-842.
Kugita, H.; Inoue, H.; Ikezaki, M.; Takeo, S. Novel reactions of nitroarenylketones with SnCl2. Chem. Pharm. Bull., 1970, 18, 2028-2037.
Hawser, S.; Lociuro, S.; Islam, K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol., 2006, 71, 941-948.
Lin, G.L.; Ednie, M.; Clark, C.; Smith, K.; Kosowska-Shick, S.; McGhee, P.; Dewasse, B.; Beachel, L.; Caspers, P.; Gaucher, B.; Mert, G.; Shapiro, S.; Appelbaum, P.C. Antistaphylococcal activities of dihydrophthalazine dihydrofolates, a family of novel antibacterial drugs by time-kill, abstract F1-3937. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC).
Peppard, W.J.; Schuenke, C.D. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic resistant staphylococcal infections. Curr. Opin. Investig. Drugs, 2008, 9, 210-225.
Collins, C.H. Microbiological methods; Butterworths: London, 1964, p. 92.
Lorian, V. Antibiotics in laboratory medicine; Williams and Wikins: Baltimore, London, 1980, p. 1014.
CLSI approved standards M100-S15. Performance standards for antimicrobial susceptibility testing; clinical and laboratory standards institute; CLSI: Wayne, PA, 2008.
Wayne, P.A. CLSI approved standards M100-S15. Performance standards for antimicrobial susceptibility testing; clinical and laboratory standards institute; CLSI, 2008.
Murray, P.R.; Baron, E.J. Manual of clinical microbiology, 6th ed.; Washington, D.C: ASM Press, 2007.
Guven, O.O.; Erdogan, T.; Goker, H.; Yildiz, S. Synthesis and antimicrobial activity of some novel phenyl and benzimidazole substituted benzyl ethers. Bioorg. Med. Chem. Lett., 2007, 17, 2233-2236.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed.; Approved standard. Document M7- A6. Clinical and Laboratory Standards Institute, Wayne, PA, 2003.
Performance standards for antimicrobial susceptibility testing; 18th informational supplement. Document M100-S19, Clinical Laboratory Standards Institute, 2009.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [813 - 832]
Pages: 20
DOI: 10.2174/1573406415666190206231555
Price: $65

Article Metrics

PDF: 22